Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Research & Development (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Research & Development for 6 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • Quarterly Research & Development fell 31.73% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.2 million through Dec 2025, up 6.33% year-over-year, with the annual reading at $114.2 million for FY2025, 6.33% up from the prior year.
  • Research & Development for Q4 2025 was $20.0 million at TScan Therapeutics, down from $31.7 million in the prior quarter.
  • The five-year high for Research & Development was $32.6 million in Q2 2025, with the low at $7.3 million in Q1 2021.
  • Average Research & Development over 5 years is $20.7 million, with a median of $21.5 million recorded in 2023.
  • The sharpest move saw Research & Development surged 144.38% in 2021, then plummeted 31.73% in 2025.
  • Over 5 years, Research & Development stood at $12.6 million in 2021, then rose by 23.76% to $15.6 million in 2022, then surged by 43.59% to $22.4 million in 2023, then soared by 31.01% to $29.4 million in 2024, then tumbled by 31.73% to $20.0 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $20.0 million, $31.7 million, and $32.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.